Quick Facts

• Treats: Elevated levels of total cholesterol and low-density lipoprotein (LDL) cholesterol (often called "bad cholesterol").
• Benefit: Reduces the risk of serious cardiovascular events, including myocardial infarction (heart attack) and cerebrovascular accident (stroke), in patients with existing heart disease or increased risk factors.
• Used For: Primary hyperlipidemia and mixed dyslipidemia, as an adjunct to non-pharmacologic measures like diet modification.

---

Therapeutic Use and Indications

Симвастатин-АЛСИ is prescribed as a component of an overall regimen, including diet and exercise, to manage specific lipid disorders. Its primary use is to reduce elevated concentrations of total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in the bloodstream. This therapeutic effect helps to decrease the accumulation of fatty deposits on artery walls, a process known as atherosclerosis.

In addition to treating hyperlipidemia, this medicine is indicated to reduce the risk of critical coronary events. Specifically, it can lower the incidence of non-fatal myocardial infarction, stroke, and the requirement for revascularization procedures in individuals diagnosed with coronary heart disease, diabetes, or other conditions that place them at high risk of cardiovascular complications.

Who can and cannot use Симвастатин-АЛСИ — Official Regulatory Information

The eligibility profile for Simvastatin is strictly defined by regulatory documents, distinguishing between approved populations, absolute contraindications, and groups requiring conditional use.

Eligibility Scope

Classification	Population/Condition	Regulatory Status
Contraindicated	Active liver disease, including unexplained persistent transaminase elevations	Absolute Non-Eligibility
	Pregnancy and Lactation	Contraindicated
Allowed	Adults with primary hyperlipidemia or high cardiovascular risk	Standard Labeled Use
	Adolescents (10–17 years) with Heterozygous Familial Hypercholesterolemia (HeFH)	Established Pediatric Use
Conditional Use	Patients with severe renal impairment (CrCl < 30 mL/min)	Caution and Restricted Initial Dose
	Patients with uncontrolled hypothyroidism or other risk factors for myopathy	Caution and Monitoring

Eligibility Classifications

Official labeling contraindicates Simvastatin use due to specific physiological states (active liver disease, pregnancy, breastfeeding) and certain drug interactions. Caution is required for patients with predisposing factors for muscle toxicity, such as advanced age (ge 65 years) or severe renal impairment. Use in children under 10 years is generally not established.

Interactions with other medicines and products

Official regulatory information classifies interactions with Simvastatin-ALSI into categories that dictate specific usage constraints.

Contraindicated Combinations

The most restrictive interactions involve substances that significantly increase the concentration of the active ingredient, Simvastatin, in the bloodstream. Due to the high risk of muscle toxicity (myopathy/rhabdomyolysis), co-administration with potent CYP3A4 inhibitors is formally prohibited. This group includes certain Azole Antifungals (such as Itraconazole and Ketoconazole), Macrolide Antibiotics (such as Erythromycin and Clarithromycin), HIV Protease Inhibitors, and agents like Ciclosporin, Danazol, and Gemfibrozil.

Interactions Requiring Dosage Restriction

Co-administration with other documented inhibitors of drug metabolism, such as certain Calcium Channel Blockers (Verapamil and Diltiazem) and Amiodarone, results in a moderate increase in Simvastatin exposure. Regulatory labels mandate that the maximum daily Simvastatin dose must not exceed a specified, lower limit when taken with these medicines.

Food, Supplements, and Other Interactions

Consumption of large quantities of Grapefruit Juice is prohibited because it increases Simvastatin plasma levels. The medicine's absorption is reduced by Bile Acid Sequestrants, requiring a mandatory time separation rule where Simvastatin must be administered at least two hours before or four hours after the sequestrant. Other Fibrates and lipid-modifying doses of Niacin (ge 1 g/day) also create a documented additive risk of muscle toxicity.

How Simvastatin-ALSI Works: Mechanism of Action

Simvastatin-ALSI initiates its action primarily within the liver via a two-part mechanistic sequence. The drug is administered as an inactive lactone prodrug that undergoes hepatic hydrolysis to become the pharmacologically active beta -hydroxyacid form.

The active form acts as a competitive inhibitor of HMG-CoA reductase, the enzyme that governs the rate-limiting step of the mevalonate pathway. By inhibiting this enzyme, the drug suppresses the synthesis of cholesterol within the body. This action results in reduced intracellular cholesterol concentration within liver cells, which activates a necessary feedback mechanism.

This intracellular deficit triggers the SREBP-2 signaling pathway, resulting in the upregulation of LDL receptors on the hepatocyte surface. These receptors bind to LDL-C particles in the blood plasma, enabling their increased systemic clearance and subsequent catabolism. Because this mechanism depends on the synthesis of new LDL receptors, the resulting physiological change has an inherent time delay.

Administration Protocol

Симвастатин-АЛСИ, which is Simvastatin, is prescribed for long-term, systemic management and is administered exclusively via the oral route as a tablet. The established regimen requires a single daily dose taken specifically in the evening. This timing is intended to optimize the medicine's effect by aligning with the body's natural cycle of cholesterol production.

Dosing and Scheduling

The medicine may be taken with or without food, providing flexibility for daily intake. However, a critical administration constraint for proper use is the complete avoidance of grapefruit juice.

Instruction Category	Regimen Description
Standard Adult Dose	Typically initiated at 10 mg to 20 mg once daily, with a maintenance range generally up to 40 mg.
Maximum Dose Threshold	The maximum dose for initiation in new patients is 40 mg. The 80 mg dose is restricted to individuals who have been taking it chronically without muscle-related complications.
Dose Adjustment Interval	Dosage changes, when necessary, occur at intervals of not less than four weeks.
Missed Dose Protocol	If a dose is missed, the standard procedure is to take the dose as soon as possible, but never double the next dose

Population-Specific Use

For patients with severe renal impairment, the daily dose typically should not exceed 10 mg. For pediatric patients with specific types of high cholesterol (HeFH), the typical starting dose is 10 mg, with a maximum set at 40 mg daily.

These instructions create a standardized framework for the medicine’s proper administration, ensuring it is used precisely as intended for its therapeutic purpose.

---

Overview of Research Evidence for Simvastatin-ALSI

Studies related to the active component, Simvastatin, constitute a broad base of data derived from Randomized Controlled Trials (RCTs). These investigations were carried out to explore the relationship between the active component and both lipid levels in the blood and long-term health outcomes, such as serious cardiovascular events.

---

Evidence for Secondary Prevention of Cardiovascular Events

This evidence is rooted in large-scale, multi-year RCTs that examined the use of the active component in adults with established heart disease (Secondary Prevention). Research examined the effect in adults with a previous history of a cardiovascular event, such as a heart attack or stroke, monitoring outcomes like all-cause mortality and the occurrence of new non-fatal myocardial infarction. The studies explored the incidence of serious cardiovascular events, and patterns described documented fewer events in the treated populations compared to the control groups.

Evidence for Primary Prevention in High-Risk Patients

Large-scale RCTs were evaluated in populations considered to be at high risk for a first cardiovascular event, such as those with diabetes or significantly elevated cholesterol levels. These studies explored whether the incidence of a first major cardiovascular event was observed less frequently during the study period compared to placebo. Follow-up durations were typically limited to around five years in core RCTs, meaning long-term effects beyond that timeframe are not fully established.

---

Research on the Effect on Lipid Levels and Dyslipidemia

Research examined the effect of the active component on key blood lipid levels across various forms of hypercholesterolemia. Short-term clinical trials data show patterns related to lower measured levels of LDL cholesterol and Total Cholesterol in the observed populations. Research provides insight into short-term changes in these outcomes.

Evidence in Special Populations and Specific Groups

The active component was evaluated in a limited number of pediatric patients (ages 10-17) with Heterozygous Familial Hypercholesterolemia (HeFH). Sample sizes were modest in these specific studies, and long-term effects are not fully established for this younger population.

Key Studies & References

1. NICE Guideline: Cardiovascular disease: risk assessment and reduction, including lipid modification

Common questions about Симвастатин-АЛСИ (FAQ)

Q: Is Симвастатин-АЛСИ considered a treatment for all types of high cholesterol?

Official documents indicate that the medicine is used for managing high blood lipids, including primary hypercholesterolemia and mixed dyslipidemia. It is also indicated for specific genetic conditions, such as Heterozygous Familial Hypercholesterolemia (HeFH).

Q: Are changes in memory or confusion reported as possible side effects of Симвастатин-АЛСИ?

Rare post-marketing reports of cognitive impairment, such as memory loss, forgetfulness, and confusion, have been associated with statin use. These reported symptoms are generally described as not serious and are typically noted to be reversible upon discontinuation of the medication.

Q: Is there a link between taking Симвастатин-АЛСИ and feelings of dizziness or issues with balance?

The official safety profile includes dizziness among the less common side effects that have been reported. Some safety information also indicates that the risk of falls may be noted, particularly in older patients.

Q: Can Симвастатин-АЛСИ cause or worsen symptoms of depression or mood changes?

Post-marketing safety surveillance has included reports describing mood changes, such as irritability and depressed mood, associated with statin therapy in some individuals.

Q: Does Симвастатин-АЛСИ affect blood sugar levels, and is there a link to diabetes risk?

Official documents contain updated safety warnings regarding blood sugar levels. Increases in blood sugar (glucose) and glycosylated hemoglobin (HbA1c) have been reported with statin use, noting a small risk of developing Type 2 diabetes.

Q: What is the difference between mild muscle discomfort and the serious muscle condition rhabdomyolysis?

Official documents describe muscle toxicity (myopathy) as muscle weakness, pain, or tenderness. In contrast, rhabdomyolysis is described as a rare, severe form of muscle breakdown that is associated with the potential for acute renal failure, and it is listed as a serious adverse reaction.

Q: Is hair loss a reported side effect associated with Симвастатин-АЛСИ?

Hair loss (alopecia) is explicitly listed as a post-marketing adverse reaction in the regulatory safety profile under 'Skin and Subcutaneous Tissue Disorders,' suggesting it is a relatively rare occurrence.

Q: Do side effects from Симвастатин-АЛСИ usually get better or worse over time?

Official information specifically notes that the risk of muscle toxicity (myopathy), including the most serious forms, may be highest during the first 12 months of therapy.

Q: What signs of liver damage should a patient be aware of while taking Симвастатин-АЛСИ?

Regulatory documents describe symptoms such as unusual weakness, loss of appetite, upper stomach pain, dark-colored urine, or a yellowing of the skin or eyes. These changes may signal potential liver problems and warrant attention.

Q: Are allergic reactions to Симвастатин-АЛСИ common or rare?

Serious systemic allergic reactions, such as anaphylaxis, are classified as Very Rare in the official safety profile. Other symptoms that may be allergic in nature, such as rash and itching (pruritus), are classified as Uncommon.

Q: What is the general recommendation regarding alcohol consumption while taking Симвастатин-АЛСИ?

Official warnings note that consuming substantial quantities of ethanol (alcohol) while using the medication may increase the risk of liver problems. This risk is a factor that patients should discuss with a healthcare provider.

Q: Does St. John's wort affect how Симвастатин-АЛСИ works in the body?

Official information suggests that St. John’s wort may decrease the drug's effect by affecting its metabolism in the body. Specific monitoring or an adjustment to the drug's regimen may be considered if these products are used together.

Q: Is there a known interaction between colchicine (for gout) and Симвастатин-АЛСИ?

Regulatory documents note that caution is required when Simvastatin is used alongside colchicine (a gout treatment). Myopathy, including rhabdomyolysis, has been reported in patients taking this combination.

Q: Is the potential for drug interactions higher when taking a high dose of Симвастатин-АЛСИ?

Official documents explicitly state that the risk of muscle toxicity (myopathy), which is often triggered or worsened by drug interactions, is highest when using the 80 mg dose strength.

Q: Why is taking Симвастатин-АЛСИ during pregnancy or while breastfeeding generally not recommended?

Regulatory documents prohibit use during pregnancy and breastfeeding because the medicine's mechanism involves inhibiting cholesterol synthesis. Cholesterol and its derivatives are necessary for normal fetal development, and the drug's action has been associated with the potential for fetal harm.

Q: Are older patients (over 65) at a higher risk for specific side effects from Симвастатин-АЛСИ?

Advanced age, defined as 65 years or older, is officially listed as one of the predisposing factors for an increased risk of myopathy (muscle toxicity) in official regulatory information.

Q: Is Симвастатин-АЛСИ typically prescribed for people with a history of alcohol abuse?

Official information notes that caution is required for use in patients with a history of heavy alcohol use. This is due to the potential for an increased risk of liver problems, which is a known safety concern.

Q: Is it safe to drive a car or operate machinery while taking Симвастатин-АЛСИ?

The drug’s safety profile notes potential side effects such as dizziness and confusion. Official guidance indicates that caution may be necessary when driving or operating machinery if a person experiences these or other related effects.

Q: Are there any differences in the use of Симвастатин-АЛСИ for men versus women?

Post-marketing safety reports have included observations that women may be more likely than men to report muscle-related side effects during therapy.

How to Store and Dispose of Simvastatin-ALSI: Official Requirements

Simvastatin-ALSI must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The medication must be protected from light, moisture, and excessive heat, and it should not be frozen.

Tablets must be kept in their tightly closed container or original packaging. It is a mandatory requirement to store Simvastatin-ALSI out of the sight and reach of children to prevent accidental ingestion.

Disposal

When disposing of unused or expired Simvastatin-ALSI, the medication must not be flushed down a toilet or poured down a drain. Disposal should preferably occur through an authorized drug take-back program. If no such program is available, the product may be discarded with household trash following the specific FDA-recommended steps for non-flushable medicines.